Cambridge Healthtech Institute’s MOLECULAR EVOLUTION

Cambridge Healthtech Institute chi at healthtech.com
Thu Feb 27 13:14:29 EST 1997

Cambridge Healthtech Institute’s 
April 24-25, 1997  Copley Plaza, Boston, Massachusetts
Co-sponsored by: Canji, Inc., Pharmacia Biotech, and PharmaGenics
A large number of biomedical applications involve the search for
compounds with improved activity or performance. The application of
molecular evolution is proving to be extremely well suited for this
purpose, particular for identification of nucleic acids or peptides.
Genetics makes it possible to employ sequential rounds of screening
and selection, followed by further mutation, to allow for the 
generation of compounds adapted for a desired target or under specific
conditions. Phage display and other related techniques have been used
extensively for this purpose. Examples of the development of
antibodies, mutated proteins, and a range of research, selection, and
therapeutic applications are covered in detail. Learn how leaders in
this field are taking advantage of the power of this technology and
how you might benefit from making greater use of it by attending this
timely event. 

In Vivo and In Vitro Applications of Nucleic Acid Ligands
	Dr. Daniel W. Drolet, NeXstar Pharmaceuticals (confirmed)
Mirror-Image RNA Ligands
	Dr. Jens P. Furste, Freie Universitst Berlin (confirmed)
Aptamer Evolution:  Prospects for Diagnostics and Therapeutics
	Dr. Andrew D. Ellington, Indiana University (confirmed)
Ribozymes from Random Sequences:  Dr. David Bartel, Whitehead 
	Institute and Massachusetts Institute of Technology (confirmed)

Exploiting the Diversity of Large Human Antibody Libraries
	Dr. John McCafferty, Cambridge Antibody Technology Ltd. (confirmed)
Molecular Evolution of Proteins, Pathways and Viruses by DNA Shuffling
	Dr. Willem Stemmer, Maxygen, Inc. (confirmed)
In Vitro Selection of Peptides Acting on NMDA Glutamate Receptors
	Dr. Min Li, John Hopkins School of Medicine (confirmed)
Synthesis Based Molecular Design of Antibodies and Proteins:  
	Dr. William D. Huse, Ixsys, Inc. (confirmed)
	Dr. Manuel Baca, Genentech, Inc. (confirmed)

Cloning Novel Genes with Phage-Displayed Peptide Ligands
	Dr. Brian Kay, University of North Carolina at Chapel Hill 
Adenovirus Expression Systems in Conjunction with Autofluorescent 
Proteins:  Potential Use in the Screening of Peptide Libraries
	Dr. Luc Peloquin, Quantum Biotechnologies Inc. (confirmed)
Functional Epitope Mapping by Negative Selection of Phage-Displayed 
Randomized Protein Libraries
	Dr. Laurent Jespers, Flanders Interuniversity Institute for 
	Biotechnology 	(confirmed)
Automated Affinity Based Screening Using Serial Column Chromatography 
Interfaced with Mass Spectrometry
	Dr. Satish Jindal, ChemGenics Pharmaceuticals (confirmed)
Use of Combinatorially Generated Phage Displayed Ligands to Develop 
Engineered Microprotein Ligands for Large Scale Biotherapeutic 
	Dr. John Maclennan, Dyax Corporation (confirmed)
Identification of Optimal Ligands for Protein Domains Using Oriented 
Peptide Libraries
	Dr. Zhou (Sonny) Songyang, Harvard Medical School (confirmed)

Identification of Amino Acids Critical for the Activity of a Peptide 
Mimetic of Erythropoietin and Discription of a Minimal Functional 
	Dr. Dana Johnson, R.W. Johnson Pharmaceutical Research Institute 
Combinatorial Methods and Directed Evolution Applied to Staphylococcal

a-hemolysin, a Pore-Forming Protein
	Dr. Hagan Bayley, Worcester Foundation for Biomedical Research 
Human Protein Display:  A New System for Discovering Drug Binding 
	Dr. Allan Peng, GeneMax, Inc. (confirmed)
Novel Approaches for Targeting Tumors and Inhibiting Metastasis
	Dr. Renata Pasqualini, La Jolla Cancer Research Center, The Burnham 
	Institute (confirmed)
Sampling Peptide Space for Cell-Targeting Peptides
	Dr. Stephen A. Johnston, University of Texas, Southwestern Medical 
	Center, 	(confirmed)
Cloning Using Phage Display
	Dr. Bob Shopes, Tera Biotechnology Corporation (confirmed)
Establishing Site Directed Assays Using Phage Displayed Libraries of
Peptides and Antibodies
	Dr. Arthur J. Blume, DGI BioTechnologies, L.L.C. (confirmed)

More information about the Embl-db mailing list

Send comments to us at biosci-help [At] net.bio.net